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Summary: Studies are reported on the reaction kinetics of the glucose assay according to Trinder which involves the
specific oxidation of glucose by glucose oxidase and the determination of the hydrogen peroxide released by means
of phenol and 4-aminophenazone in the presence of peroxidase. The results have been used to develop a general
kinetic fixed-time method for the analysis of glucose in whole blood and serum. The single reagent method has been
adapted to the ENI GEMSAEC centrifugal analyzer and to the Abbott AB A-100 analyzer. The procedures exhibited
excellent precision and the results correlated well with those obtained by the hexokinase method. Linearity was
achieved from 3 to 64 mmol/1 glucose for the GEMSAEC method, and from 3 to 33 mmol/1 glucose for the ABA-100
method. Reagent or sample blank corrections were not necessary. There were no interferences from various drugs,
hemoglobin, bilirubin, or lipemia.
Enzymatische Methode zur Bestimmung von Glucose in Blut und Serum auf kinetischer Basis mittels A nalysenauto·
muten
Zusammenfassung: Wir untersuchten die Reaktionskinetik des Glucose-Tests nach Trinder, bei dem Glucose durch
Glucose-Oxidäse oxidiert und das freigesetzte Wasserstoffperoxid mittels Phenol und 4-Aminophenazon in Gegen-
wart von Peroxidase bestimmt wird. Die Ergebnisse wurden zur Entwicklung eines allgemein anwendbaren kinetischen
„fixed-time"-Verfahrens für die Analyse von Glucose in Blut und Serum benutzt. Die mit einem Einkomponenten-
Reagenz durchführbare Methode wurde auf die Analysenautomaten ENI Gemsaec und Abbott ABA-100 adaptiert. Die
einzelnen Varianten der Methode ergaben bei der Untersuchung von Präzision und Richtigkeit ausgezeichnete Resultate.
Der Linearitätsbereich erstreckte sich beim GEMSAEC-Verfahren von 3 bis 64 mmol/1 Glucose, beim ABA-lOO-Ver-
fahren von 3 bis 33 mmol/1 Glucose. Die Bestimmung von Reagenz- oder Probenleerwerten war nicht erforderlich.
Störungen durch verschiedene Pharmaka, Hämoglobin, Bilirubin und Lipämie wurden nicht beobachtet.
Introduction
Among the many methods for blood or serum glucose
determination, the procedures based on the oxidation
of glucose by glucose oxidase (EC 1.1.3.4) are perhaps
most widely used in clinical laboratories (1-2):
glucose
jfcD-Glucose + H2O + O2 °^ijasfi D-glucono- - (
lactone + H2O2
The enzyme is specific for ß-glucose which comprises
about 64% of total serum glucose (3). Since the
*) Presented in part at the GEMSAEC Users Club Meeting,
Göteborg, Sweden, February 9-10,1976, at the 7th Inter-
national Symposium on Clinical Enzymology, Venice, Italy,
April 5-7,1976, and at the Kongreß der Deutschen Gesell-
schaft für Labdratpriumsmedizm, Berlin, Germany, May
20-22,1976.
remaining -glucose is converted to the /3-form by muta-
rotation, the total glucose content of the sample is
covered by that reaction (1).
The hydrogen peroxide released in the glucose oxidase
reaction is commonly determined with peroxidase (EC
1.11.1.7) and a suitable hydrogen donor which is oxidized
to a colored compound (1—2). In the modification
according to Trinder (4), the following indicator reaction
is used:
^V
peroxidase ̂  J [ * ̂
O^VSlHa
^z^
Amox ̂  505
+ 4 H 2 0
nm
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This colometric method so far has been carried out as
an end^point or equilibrium procedure. Little effort
appears to have been expended on the elaboration of a
kinetic procedure which potentially can improve the
speed, specifity and simplicity of the assay.
It is well recognized that enzymatic substrate analysis
can be based on reaction rate measurements, if the
Michaelis constant Km of the enzyme is much greater
than the initial substrate concentration (5). In this case,
a reaction obeying pseudo-first order kinetics is ob-
tained which can be easily measured on automated
instruments by means of kinetic fixed-time methods (6).
An inspection of the properties of glucose oxidase
reveales (7) that this enzyme, due to its high Km -value
of about 30—110 mmol/1, is ideally suited for kinetic
analysis of glucose.
The present study was undertaken to examine the
feasibility of a kinetic procedure for glucose determi-
nation with use of the assay according to Trinder. The
first step in this treatment was to analyze in detail the
kinetics of the reaction system. The results obtained
enabled us to develop a general kinetic fixed-time method
for routine analysis of blood and serum glucose. The
method has been adapted for use with two commercially
available automated instruments. Each analytical
approach has been characterized with respect to precl·
sion, accuracy and susceptibility to interference.
Materials and Methods
Apparatus
An ENI GEMSAEC centrifugal analyzer including ROTO-
LOADER (Electro-Nucleonics, 368 Passaic Ave., Fairfield,
N. J. 07006), an ABA-100 analyzer (Abbott Scientific
Products Division, South Pasadena, Calif. 91030), and an
AutoAnalyzer I (Technicon Instruments, Tarrytown, N. Y.
10591) were used for the automated determinations. The
GEMSAEC analyzer was interfaced to a DEC-PDP 8 computer
and had a DECtape for additional program storage (Digital
Equipment, Maynard, Mass. 01754). The manual assays were
carried out on Model 1101 M spectrum line photometers
(Eppendorf Ger tebau Netheler & Hinz, 2 Hamburg, Germany).
Reagents
Test kit "Glucose, GOD/PAP method" cat. No. 166391; test kit
"Glucose, hexokinase method", cat. No. 124346; test kit "Blood
sugar, GOD/PAP method", cat. No. 124001; standard "Precimat
Glucose" (5.55 mmol/1 Z>-glucose), cat. No. 125555; standard
"Precimat-D Glucose" (505 μηιοΐ/ΐ Z)-glucose), cat. No. 125580;
uranyl acetate solution (3.77 mmol/1 of physiological saline),
cat. No. 125415; perchloric acid (0.33 mol/1), cat. No. 125369;
and α-methyl-DOPA were all from Boehringer Mannheim, P. O.
Box 51, D-6800 Mannheim 31, Germany. D-glucose, bilirubin
and ascorbic acid were purchased from E. Merck, D-6100 Darm-
stadt, Germany. From the constituents of the test kit "Glucose,
GOD/PAP method" a single reagent was prepared which con-
tained phosphate buffer (0.1 mol/I, pH 7.0), phenol (11 mmol/1),
4-amino-phenazone (0.75 mmol/1), glucose-oxidase (έ 13 kU/1),
and peroxidase (^ 0.8 kU/1). This reagent was used for both, the
kinetic procedures with the GEMSAEC or with the ABA-100 and
the manual end-point procedure according to Trinder. It was
stable for at least 2 months at 4 °C.
Procedures
Deproteinization (1)
1.0 ml of uranyl acetate solution was added to 0.1 ml of
capillary blood or serum. After careful mixing the suspension
was centrifugated for 10 min at 3000 r. p. ni. Aliquots of the
supernatant were submitted to the manual endpoint procedure
according to Trinder or to the automated kinetic assays.
GEMSAEC
50 μΐ of calibration standard (505 μιτιοΐ/ΐ) or deproteinized
sample was pipetted into cavity Β of the transfer disc, followed
by 150 μΐ of physiological saline diluent; 500 μΐ of reagent was
pipetted into cavity C of the transfer disc. The disc was placed
into the GEMSAEC analyzer which was operated at a wavelength
of 510 nm and at 25 °C. The first absorbance reading was taken
35 s after the start of the run (IR = 10), the second reading 90s
later. The sample ring was loaded in the following sequence:
position 1, distilled water; position 2, standard; and positions
3-16, control sera and patients' samples. There was no need for
sample or reagent blanks.
Using native serum as a specimen, the procedure given above was
followed. However the volume of calibration standard (5.55
mmol/1) and serum to be pipetted into cavity B of the transfer
disc was reduced to 5 μΐ.
For the calculation of the results, the computer program
TC = 5 was used, which is designed for routine kinetic fixed-
time analysis (ElectrorNucleonics Europe, Tramsingel 39, Breda,
Holland).
ABA-100
50 μΐ of calibration standard (505 μ mo 1/1) or deproteinized
sample and 500 μΐ of reagent were pipetted into the 32-place
plastic euvet. Using the light filter 500 nm/600 nm, the first
absorbance reading was taken at 20 s after the initiation of
the run, and the second reading was taken 300 s later. The
incubation temperature was 37 °C. The samples in positions
0-2 were distilled water, the sample in position 3 was the
standard, and the samples in positions 4-31 were control sera
and patients' specimens. It was not necessary to determine
reagent or serum blanks. As with the GEMSAEC procedure
the volume of standard (5.55 mmol/1) or samples was reduced
to 5 μΐ if native serum was submitted to the assay.
Other procedures
The manual glucose oxidase-based endpoint determinations
were carried out as described by Trinder (4). However, 0.2 ml
of sample and 2.0 ml of reagent were used. Moreover, the in-
cubation was performed for 35-40 min at 20-25 °C, and the
measuring wavelength was Hg 546 nm. The hexokinase
(EC 2.7.1.1) method was conducted as described by Bergmeyer
et al. (8). The AutoAnalyzer I was operated according to the
procedure of Trinder (4), using the test kit "Blood sugar,
GOP/PAP method". The erythrocyte hemolysate used for the
examination of hemoglobin interference was prepared as reported
by Gochman et al. (9). The content of triglycerides or
cholesterol of human sera was determined enzymatically as
described previously (10, 11).
Results and Discussion
Reaction Kinetics
Figure 1 represents the time course of the overall reaction
of the assay, using a sernilogarithinic plot. In a plot of that
kind, first- or pse do-first-order behaviour is indicated by
straight lines. The slope of these lines is proportional to the
rate constant of the reaction (12).-The Figure demonstrates
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Fig. 1. Effect of glucose oxidase concentration on time course of reaction.
A^ absorbance at time t, Aoo, absorbance after completion of reaction. ·, o, 13 kU/1 glucose oxidase. *, Δ, 23 kU/1 glucose
oxidase. ·, o, 61 kU/1 glucose oxidase.
Samples: Curves I—HI, glucose standard (22.2 mmol/1). Curves IV-VI, glucose standard (5.55 mmol/1). The response curves
were recorded at Hg 546 nm through an Eppendorf photometer by simulating the GEMSAEC assay.
that the velocity of the reaction is first order overall in
glucose concentration. However, the reaction displays a
distinct two phase rate characteristic. It passes through a
fast period in the beginning, after which it enters into a
slower period.
The Figure also shows that the rate constant of the fast
early stage of the reaction increases, whereas the length of
this stage decreases with increasing glucose oxidase con-
centration. In contrast, the rate of the second portion of
the reaction is not influenced by the concentration of the
glucose oxidase enzyme. Figure 2 illustrates that the velo-
city of this reaction phase can be increased by the
addition of mutarotase to the reagent. No changes in the
reaction rate are to be observed if the concentration of






Fig. 2. Effect of added mutarotase or peroxidase concentration
oil time course of reaction.
·, 2 kU/1 mutarotase. Δ, 20 kU/1 mutarotase. o, 0.8 kU/1
peroxidase. ·, 1.6 kU/1 peroxidase.
Sample: glucose standard (22.2 mmol/1). For further
details see legend of Figure 1.
We conclude from these observations that in the initial
phase of the reaction, the oxidation of the /3-glucose
portion of the sample by glucose oxidase is the rate
limiting step of the whole reaction sequence. Because
of the high Km -value of the enzyme, the reaction follows
pseudo-first order kinetics. After the consumption of
0-glucose, the subsequent formation of this molecule
from the α-glucose portion of the sample by spontaneous
mutarotation becomes rate-limiting. The exact pseudo-
first-order behaviour of this isomerization process has
long been recognized (3).
From the foregoing it is evident that the reaction system
can be kinetically described as
where X denotes α-glucose concentration, Υ 0-glucose
concentration, and Ζ hydrogen peroxide concentration,
kn, k_j, and k+2 are the pseudo-first-order rate con-
stants of the respective reactions. The following differen-




— =k+ iX-k_1Y-k f 2Zdt
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Here XQ and Y0 are the initial concentrations of α-glucose
and 0-glucose, respectively. At time t = 0, Y0 = Κ Χ0,
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where K is the equilibrium constant of the mutarotation
process. f
To solve the differential equations 1—3 we applied the
method of Laplace transformation with reference to
Rescigno et al. (13) and Bromtein et al. (15); Utilizing the
Laplace transforms x, y, and z of X, Y, arid Z equations
1—3 become
sy - Y0 = k+1x - k_i
sz-Z0 = k+2y
- k+2y
The equations can be rearranged to give
(s + k_! + k+2)y = Y0
-k+2y + sz = 0
where s is a real or a complex number.











in which D is the determinant of the coefficient matrix
and Di (i = 1,2, 3) are determinants obtained from D by
replacing the i~th column by the column of constant terms,
i. e. the right-hand side of the above system of equations.
It is assumed that D ̂  0. By setting a + b = k+1 + k_j
+ k+2 and ab = k+1k+2 one obtains
D = s (s + a) (s + b)
x = X0s + _! + k+2)
(s + a) (s + b)
z = -
(s + a) (s + b)
Y0k+2s + Xpk+ik+2 + Yoknk+2





Application of the reverse Laplace transformation to
equations 15—17 and subsequent rearrangement yields
the final solutions
γ = ~ Y° (a " "at
(eq 18)
(eq 19)
Z = Y0 -
- X0a <fc - k+2)j
+ Y (b - k+2)] at
-bt (eq 20)
Equation 20 can be used to calculate the change in con-
centration Z during the fixed-time interval At = t2 — tj
The result indicates (equation 21) that
ΔΖ = Z2 - =gU^·*-'- (eq 21)
ΔΖ is a linear combination of the initial glucose concen-
trations Xo and Y0. Because Y0 = KXo, AZ is directly
proportional to the total amount of glucose, providing
the reading times 1χ and t2, the terms k+χ, k^ \ and k+2,
resp. a and b are held constant during the measurement.
All of these requirements can be easily achieved on
automated instruments. Since two moles of Ζ are rapidly
converted to one mol of absorbing product (II), the
absorbance ehaage measured during any selected fixed-
time interval is also a linear function of the initial glucose
concentration. For these reasons, the kinetic fixed^time




The linearity of the automated methods was checked by
measuring a series of aqueous glucose standards which
had been prepared using weighed quantities of high-
purity Z)-glucose. The results observed with use of the
GEMSAEC method are shown in figure 3. the linearity
extended up to a concentration of 64 mmol/1 glucose.
The Figure also demonstrates that the sensitivity of
the procedure in the normal range was reasonable. The
upper limit of linearity for the ABA-100 method was
33 mmol/1 glucose.
Precision
Data on the within-run precision of the present methods
are provided in table 1. The results illustrate the good
reproducibility of each procedure. D y-to-d y precision
was determined by assaying two lots of the control serum
"Precilip" (Boehringer Mannheim) during 10 days. The
glucose content of this serum was 5.42 or 4.80 mmol/1.
We found a coefficient of variation of 2.6% for the
GEMSAEC method, and a value of 2.9% for the ABA-100
metiiod, if deproteinized sera were analyzed. Without de-
proteinization, we obtained CV-valiie$ of 3.4% and
3.2% for the respective method. . .
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Fig. 3. Fixed-time absorbance change as a function of glucose
concentration (with the GEMSAEC).








































































5 10 15 20 25 30 35
Glucose (hexokinase method) [mmol/l]
Fig. 4. Comparison oi present GEMSAEC method (y) with
manual hexokinase method (x) for glucose in depro-
teinized human sera.
The samples were deproteinized with uranyl acetate
(GEMSAEC method) or with perchloric acid (hexokinase
method), n = 54; y = 1.02x - 0.033; 95 % confidence inter-
val of slope: 1.00 to 1.03; 95% confidence interval of y-
intercept: - 0.23 to 0.17. r = 0.999; mean χ = 11.6;







The glucose concentration of deproteinized human sera
was determined by the automated kinetic methods and,
in parallel, by the manual hexokinase reference method
(8). The results of these correlation studies were excellent
(fig. 4 and 5). Likewise satisfactory linear regression para-
meters were obtained if capillary blood was used as the
sample instead of serum (fig. 6). In this case, two different
samples were taken from each patient. After deproteinL·
zatipn, one sample was submitted to the kinetic assay and
the other one to the hexokinase method; the coefficient
of correlation obtained was lower tlian in the preceding
studies. However, the slope and the y-iritercept of the
regression curve were, within the 95% confidence limits.
Moreover, a paired t-test showed no significant differ-
ence between the results obtained by the two methods
(t = 0.84, critical t = 2.23 t 95 % confidence limits).
0 5 10 15 20
Glucose (hexokinase method) [mmol/l]
Fig. 5. Comparison of present ABA-100 method (y) with
manual hexokinase method (x) for glucose in depro-
teinized human sera.
The samples were deproteinized with uranyl acetate
(ABA-100 method) or with perchloric acid (hexo*
kinase method), n = 60; y = 0.98x - 0.077; 95% con-
fidence interval of slope: 0.96 to 0.99; 95 % confidence
interval of y-intercept^- 0.26 to 0.10; r = 0.997;
mean x = 8.66; mean y = 8.41.
Figures 7 and 8 illustrate that the kinetic assay can also
be successfully applied to native human sera. However,
it must be noted that in this instance the measured
values are generally 6-11 %*higher than those obtained
for the sera after deproteinization. The molecular basis
for this obvious decrease of serum glucose concentration
on deproteinization is still under investigation.
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2 4 6 8
Glucose (hexokinose method) [mmol/ ]
Fig. 6. Comparison of present GEMSAEC method (y) with
manual hexokinase method (x) for glucose in capillary
blood samples.
The samples were deproteinized with uranyl acetate
(GEMSAEC method) or with perchloric acid (hexo-
kinase method), n = 39; y = 1.05 x - 0.19; 95% con-
fidence interval of slope; 0.96 to 1.14; 95 % confidence
interval of y-intercept: - 0.69 to 0.31; r = 0.969; mean







Glucose (native sera) [mmol/l]
25 30
Fig. 7. Relation between glucose values obtained by the
GEMSAEC method for human sera before and after
deproteinization.
Native sera (y). Sera deproteinized with uranyl acetate
(χ), η = 50; y = l.lOx + 0.067; 95% confidence interval
of slope: 1.07 to 1.14; 95% confidence interval of y-
intercept: - 0.33 to 0.47; r = 0.991; mean x = 10.1;
mean y = 11.2.
Interferences
Drug interferences with glucose end-point methods have
been discussed in detail by Szasz et al. (14). These
authors demonstrated that out of 43 representative
drugs only ascorbic acid, novaminsulfonic acid, and








Glucose (native sera) [mmol/l]
20
Fig. 8. Relation between glucose values obtained by the ABA-100
method for human sera before and after deproteinization.
Native sera (y). Sera deproteinized with uranyl acetate
(χ), n = 60; y = 1.04x + 0.16; 95% confidence interval of
slope: 1.03 to 1.06; 95% confidence interval of y-intercept:




Fig. 9. in vitro interference of ascorbic acid with some glucose
assays according to Trinder.
Auto Analyzer I method (I). Manual end-point method
(II). GEMSAEC method, sera deproteinized with uranyl
acetate (III). GEMSAEC method, native sera (IV).
glucose assay according to Trinder. These drugs were
shown to cause a significant decrease in glucose values
measured by the end-point procedure, if they had been
added in vitro to human sera. Only small and almost
negligible effects, however, were observed in the
corresponding in vivo experiments.
When examining the in vitro influence of the above
drugs on the kinetic assay, we obtained results like
those shown in figures 9 and 102). One important obser^
vation to make here is that the kinetic approach is to a
much less subject to drug interferences than the manual
end^point procedure or the AutoAnalyzer I procedure.
Differences in the velocity of the competitive reactions
between substrates and drugs must be the reason for this
effect. The data suggest that there is no in vivo drug
interference with the kinetic method.
2) These measurements were done by E. M nz and R. Walker
in our laboratory. - -
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05 2JD
-Methyl-OOPA [mmol/I]
Fig. 10. In vitro interference of -methyl-DOPA with some
glucose assays according to Trinder.
Manual end-point method (I). AutoAnalyzer I method
(II). GEMSAEC method, sera deproteinized with uranyl
acetate (III). GEMSAEC method, native sera (IV).
Tab. 3. Analytical recovery of glucose added to lipemic human sera
by use of GEMSAEC method.
Glucose3)
[mmol/1]
















































a) Mean values of duplicate determination.
To study the influence of colored blood constituents,
such as bilirubin or hemoglobin on the kinetic assay,
we added different amounts of these substances to a
human serum pool and measured the glucose concentra-
tion without deproteinization of the samples. The results
obtained make it obvious (tab. 2) that these substances
do not cause any interference in the assay. In addition,
no interference was found from lipemia. This is illustrated
by the result of analytical recovery studies from lipemic
human sera supplemented with known quantities of pure
glucose (tab. 3).
Tab. 2. Effect of added bilirubin or hemoglobin on the glucose





















a) Mean values of .duplicate determination.
Conclusions
OUT data show that the kinetic method described here is
more specific than the corresponding manual end-point
procedure or the AutoAnalyzer I procedure. Also, it
affords a higher sample through-put because of shorter
analysis time. Since the determination of a sample blank
can be omitted the suggested method is convenient and
reagent costs are low.
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